Evidence map›Paper›PMID 34209457›Full record

ReviewCancers2021

Myelodysplastic Syndromes in the Postgenomic Era and Future Perspectives for Precision Medicine.

Ioannis Chanias, Kristina Stojkov, Gregor Th Stehle, Michael Daskalakis, Helena Simeunovic, Linet Muthoni Njue, Annatina S Schnegg-Kaufmann, Naomi A Porret, Ramanjaneyulu Allam, Tata Nageswara Rao and 10 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 1 country.

Ioannis ChaniasDepartment of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.
Kristina StojkovDepartment of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.
Gregor Th StehleClinic of Hematology, University Hospital Basel, 4031 Basel, Switzerland.
Michael DaskalakisDepartment of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.
Helena SimeunovicDepartment of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.
Linet Muthoni NjueDepartment of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.
Annatina S Schnegg-KaufmannDepartment of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.
Naomi A PorretDepartment of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.ORCID 0000-0002-2515-1935
Ramanjaneyulu AllamDepartment of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.ORCID 0000-0002-2789-3596
Tata Nageswara RaoDepartment of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.ORCID 0000-0002-9928-5944
Rudolf BenzDepartment of Hematology and Oncology, Hospital Thurgau AG, 8596 Muensterlingen, Switzerland.ORCID 0000-0001-8198-6454
Axel RueferDepartment of Hematology and Central Hematology Laboratory, Cantonal Hospital Lucerne, 6004 Lucerne, Switzerland.
Adrian SchmidtDepartment of Internal Medicine, Clinic of Medical Oncology and Hematology, City Hospital Waid and Triemli, 8063 Zurich, Switzerland.ORCID 0000-0002-6315-2592
Marcel AdlerCenter for Medical Oncology and Hematology, Hospital Thun, 3600 Thun, Switzerland.
Alicia RovoDepartment of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.
Stefan BalabanovDepartment of Medical Oncology and Hematology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.
Georg StuessiClinic of Hematology, Oncology Institute of Southern Switzerland, 6500 Bellinzona, Switzerland.ORCID 0000-0002-1667-0637
Ulrike BacherDepartment of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.ORCID 0000-0001-8771-947X
Nicolas BonadiesDepartment of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.ORCID 0000-0001-8761-2066
On Behalf Of The Swiss Mds Study Group
University of Bern · CHInstitute of Oncology Research · CHTriemli Hospital · CHUniversity Hospital of Basel · CHUniversity of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal disorders caused by sequential accumulation of somatic driver mutations in hematopoietic stem and progenitor cells (HSPCs). MDS is characterized by ineffective hematopoiesis with cytopenia, dysplasia, inflammation, and a variable risk of transformation into secondary acute myeloid leukemia. The advent of next-generation sequencing has revolutionized our understanding of the genetic basis of the disease. Nevertheless, the biology of clonal evolution remains poorly understood, and the stochastic genetic drift with sequential accumulation of genetic hits in HSPCs is individual, highly dynamic and hardly predictable. These continuously moving genetic targets pose substantial challenges for the implementation of precision medicine, which aims to maximize efficacy with minimal toxicity of treatments. In the current postgenomic era, allogeneic hematopoietic stem cell transplantation remains the only curative option for younger and fit MDS patients. For all unfit patients, regeneration of HSPCs stays out of reach and all available therapies remain palliative, which will eventually lead to refractoriness and progression. In this review, we summarize the recent advances in our understanding of MDS pathophysiology and its impact on diagnosis, risk-assessment and disease monitoring. Moreover, we present ongoing clinical trials with targeting compounds and highlight future perspectives for precision medicine.

Indexed as

future perspectivesmyelodysplastic syndromespostgenomic eraprecision medicinetargeted therapies

Identifiers

PMID34209457
PMCPMC8267785
OpenAlexW3177289982

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.